Drug Trial Radar · NCT02034708
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Last checked: Nov 20, 2026Latest source record: Dec 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
279
Actual
Start
Jun 2014
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization (off-site assessment). 270 patients will be randomized between 2 arms defining the sequence of administration of the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14 days in between. Each patient will, therefore, receive two MRI during his/her participation in the study. The two arms consist in : * Dotarem® in the first MRI, then Gadovist®/Gadavist® in the second MRI. * Gadovist®/Gadavist® in the first MRI, then Dotarem® in the second MRI. Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems. MRI examinations will be evaluated centrally by blinded independent readers for the main evaluation criterion.
Conditions
- Primary Brain Tumor
Interventions
Dotarem®Drug
Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Gadovist®/Gadavist®Drug
Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or ExcellentTime frame: Up to 15 days after randomization
Locations
32 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Arizona Medical Center
Tucson, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
Yale University School Of Medicine
New Haven, Connecticut
Infinity Clinical Research, LLC
Hollywood, Florida
University of Michigan Health System
Ann Arbor, Michigan
Quest Research Institute
Farmington Hills, Michigan
Spectrum Health
Grand Rapids, Michigan
Washington University
St Louis, Missouri
Winthrop University Hospital Clinical Trials Center
Mineola, New York
Temple University Hospital
Philadelphia, Pennsylvania
MUSC (Medical University of South Carolina)
Charleston, South Carolina
UVM MRI Center for Biomedical Imaging
Burlington, Vermont
University of Washington Medical Center
Seattle, Washington
Fundacion Abood Shaio
Bogotá, Colombia
Fundacion Cardioinfantil Instituto de Cardiologia
Bogotá, Colombia
Instituto Nacional de Cancerologia
Bogotá, Colombia
Centro Medico Imbanaco
Cali, Colombia
Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM
Medellín, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Centro Regiomontano de Investigacion S.C.
Monterrey, Mexico
Clinical Research Institute S.C.
Tlanepantla, Mexico
Hospital CIMA
Chihuahua City, Chihuahua, Mexico
Morales Vargas Centro de Investigación S.C.
León, Guanajuato, Mexico
Centro Neurologico ABC
México, Mexico Distrito Federal, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
Winsett Rethman S.A. de C.V.
Monterrey, Nuevo León, Mexico
Ajou University Hospital
Suwon, South Korea
Chonbuk national Univ Hosp
Jeonju, Jeollabuk-do, South Korea
Chungbuk National University
Cheongju-si, North Chungcheong, South Korea
Seoul St.Mary Hospital
Seoul, Seocho-gu, South Korea
Asan medical center
Seoul, Songpa-Gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.